{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:30:53Z","timestamp":1791599453595,"version":"4.3.4"},"reference-count":54,"publisher":"American Chemical Society (ACS)","issue":"18","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22025702"],"award-info":[{"award-number":["22025702"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22494692"],"award-info":[{"award-number":["22494692"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32471256"],"award-info":[{"award-number":["32471256"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82021003"],"award-info":[{"award-number":["82021003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170146"],"award-info":[{"award-number":["82170146"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92253303"],"award-info":[{"award-number":["92253303"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010260","name":"Xiamen Southern Oceanographic Center","doi-asserted-by":"publisher","award":["23YYZP020QCB26"],"award-info":[{"award-number":["23YYZP020QCB26"]}],"id":[{"id":"10.13039\/501100010260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2804100"],"award-info":[{"award-number":["2022YFC2804100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["20720230070"],"award-info":[{"award-number":["20720230070"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013314","name":"Higher Education Discipline Innovation Project","doi-asserted-by":"publisher","award":["BP2018017"],"award-info":[{"award-number":["BP2018017"]}],"id":[{"id":"10.13039\/501100013314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"New Cornerstone Science Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Three generations of EGFR tyrosine kinase inhibitors (EGFR-TKIs) have shown clinical efficacy in nonsmall cell lung cancer (NSCLC), but acquired resistance mutations\u2500especially the cis-EGFRT790M\/C797S\u2500remain a major challenge. Here, we report the identification of a series of pyrrolo[2,3-d]pyrimidine derivatives that inhibit C797S-mediated EGFR triple mutants. Among them, compound 31r shows subnanomolar IC50 values against Ba\/F3 EGFR19del\/T790M\/C797S and Ba\/F3 EGFRL858R\/T790M\/C797S, while sparing wild-type EGFR. Its binding mode with EGFR19del\/T790M\/C797S was revealed by a cocrystal structure, providing structural insights into its potency and selectivity. Compound 31r also displays excellent kinome selectivity and drug-like properties, including good metabolic stability (T1\/2 = 5.9 h) and oral bioavailability (F = 24%). Most importantly, 31r significantly suppressed tumor growth in PC-9 EGFR19del\/T790M\/C797S xenograft models, achieving regression at 80 mg\/kg once daily. These results highlight 31r as a promising lead compound for overcoming resistance associated with third-generation EGFR-TKIs and support its further development for drug-resistant NSCLC.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c01320","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T09:29:00Z","timestamp":1757410140000},"page":"19205-19228","source":"Crossref","is-referenced-by-count":9,"title":["Discovery of\nPotent and Selective Pyrrolo[2,3-\n                    <i>d<\/i>\n                    ]pyrimidine\nDerivatives as Fourth-Generation EGFR Inhibitors\nTargeting Triple Mutations"],"prefix":"10.1021","volume":"68","author":[{"given":"Zhenhua","family":"Wu","sequence":"first","affiliation":[{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]},{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]},{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-E","family":"Yan","sequence":"additional","affiliation":[{"name":"RedCloud Bio Co., Ltd. , ,","place":["Taizhou, China, 225326"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wu","sequence":"additional","affiliation":[{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]},{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[{"name":"RedCloud Bio Co., Ltd. , ,","place":["Taizhou, China, 225326"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Li","sequence":"additional","affiliation":[{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]},{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanming","family":"Xiu","sequence":"additional","affiliation":[{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]},{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cairui","family":"Lv","sequence":"additional","affiliation":[{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]},{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Sun","sequence":"additional","affiliation":[{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]},{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]},{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoke","family":"Xu","sequence":"additional","affiliation":[{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]},{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Wu","sequence":"additional","affiliation":[{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]},{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Hu","sequence":"additional","affiliation":[{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]},{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Huang","sequence":"additional","affiliation":[{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]},{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[{"name":"RedCloud Bio Co., Ltd. , ,","place":["Taizhou, China, 225326"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6326-3906","authenticated-orcid":true,"given":"Jianming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University , , ,","place":["Shanghai, China, 200240"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Hong","family":"Yun","sequence":"additional","affiliation":[{"name":"Peking University , , ,","place":["Beijing, China, 100191"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]},{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9354-5864","authenticated-orcid":true,"given":"Xianming","family":"Deng","sequence":"additional","affiliation":[{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]},{"name":"Xiamen University , , ,","place":["Xiamen, China, 361102"]},{"name":"Xiamen University , , ,","place":["Xiamen, China, 361003"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"issue":"7216","key":"2026073102203262000_cit1","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung\nadenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"issue":"6","key":"2026073102203262000_cit2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted Therapies\nfor Lung Cancer Patients With Oncogenic\nDriver Molecular Alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"2026073102203262000_cit3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102824","article-title":"Advancements in fourth-generation\nEGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic\ndevelopment","volume":"130","author":"Corvaja","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"43","key":"2026073102203262000_cit4","doi-asserted-by":"publisher","first-page":"75712","DOI":"10.18632\/oncotarget.20095","article-title":"EGFR TKI as first-line treatment\nfor patients with advanced EGFR mutation-positive non-small-cell lung\ncancer","volume":"8","author":"Nan","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"2026073102203262000_cit5","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1158\/1078-0432.CCR-14-3154","article-title":"EGFR: The Paradigm\nof an Oncogene-Driven Lung Cancer","volume":"21","author":"Riely","year":"2015","journal-title":"Clin. Cancer\nRes."},{"issue":"3","key":"2026073102203262000_cit6","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1016\/j.cllc.2019.12.003","article-title":"Tyrosine Kinase Inhibitors for the\nTreatment of EGFR\nMutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations","volume":"21","author":"Shah","year":"2020","journal-title":"Clin. Lung Cancer"},{"issue":"20","key":"2026073102203262000_cit7","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.3390\/cancers15205079","article-title":"New Generations\nof Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction:\nStrengths and Limitations","volume":"15","author":"Attili","year":"2023","journal-title":"Cancers"},{"issue":"21","key":"2026073102203262000_cit8","first-page":"4838","article-title":"Induction of Apoptosis and Cell Cycle Arrest\nby CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine\nKinase","volume":"57","author":"Moyer","year":"1997","journal-title":"Cancer Res."},{"issue":"2","key":"2026073102203262000_cit9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0022-3565(24)35162-6","article-title":"Inhibition\nof Epidermal\nGrowth Factor Receptor-Associated Tyrosine Phosphorylation in Human\nCarcinomas with CP-358,774: Dynamics of Receptor Inhibition in Situ\nand Antitumor Effects in Athymic Mice","volume":"291","author":"Pollack","year":"1999","journal-title":"J. Pharmacol.\nExp. Ther."},{"issue":"14","key":"2026073102203262000_cit10","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/S0960-894X(01)00344-4","article-title":"Studies Leading to the\nIdentification of ZD1839\n(Iressa): An Orally Active, Selective Epidermal Growth Factor Receptor\nTyrosine Kinase Inhibitor Targeted to the Treatment of Cancer","volume":"11","author":"Barker","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"2026073102203262000_cit11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.lungcan.2011.10.023","article-title":"Icotinib (BPI-2009H), a Novel EGFR\nTyrosine Kinase\nInhibitor, Displays Potent Efficacy in Preclinical Studies","volume":"76","author":"Tan","year":"2012","journal-title":"Lung Cancer"},{"issue":"34","key":"2026073102203262000_cit12","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an Irreversible EGFR\/HER2 Inhibitor\nHighly Effective in Preclinical Lung Cancer Models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"issue":"24","key":"2026073102203262000_cit13","doi-asserted-by":"publisher","first-page":"11924","DOI":"10.1158\/0008-5472.CAN-07-1885","article-title":"PF00299804, an Irreversible Pan-ERBB Inhibitor,\nIs Effective in Lung Cancer Models with EGFR and ERBB2Mutations That\nAre Resistant to Gefitinib","volume":"67","author":"Engelman","year":"2007","journal-title":"Cancer Res."},{"issue":"5","key":"2026073102203262000_cit14","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S1470-2045(12)70087-6","article-title":"Afatinib versus Placebo for Patients with Advanced,\nMetastatic Non-Small-Cell Lung Cancer after Failure of Erlotinib,\nGefitinib, or Both, and One or Two Lines of Chemotherapy (LUX-Lung\n1): A Phase 2b\/3 Randomised Trial","volume":"13","author":"Miller","year":"2012","journal-title":"Lancet Oncol."},{"issue":"12","key":"2026073102203262000_cit15","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S1470-2045(14)70472-3","article-title":"Dacomitinib Compared with Placebo in Pretreated Patients with Advanced\nor Metastatic Non-Small-Cell Lung Cancer (NCIC CTG BR.26): A Double-Blind,\nRandomised, Phase 3 Trial","volume":"15","author":"Ellis","year":"2014","journal-title":"Lancet Oncol."},{"issue":"5","key":"2026073102203262000_cit16","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jtho.2020.11.028","article-title":"Beyond Osimertinib: The Development of Third-Generation\nEGFR Tyrosine Kinase Inhibitors for Advanced EGFR+ NSCLC","volume":"16","author":"Nagasaka","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"2026073102203262000_cit17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/14737140.2019.1604228","article-title":"Third generation\nEGFR TKI landscape for metastatic EGFR mutant non-small cell lung\ncancer (NSCLC)","volume":"19","author":"Tan","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"10","key":"2026073102203262000_cit18","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1021\/acs.jmedchem.7b01310","article-title":"Recent Progress\nof Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors\nagainst C797S Resistance in Non-Small-Cell Lung Cancer","volume":"61","author":"Chen","year":"2018","journal-title":"J. Med. Chem."},{"issue":"5","key":"2026073102203262000_cit19","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/med.21488","article-title":"Targeting\nEGFR(L858R\/T790M) and EGFR(L858R\/T790M\/C797S) resistance mutations\nin NSCLC: Current developments in medicinal chemistry","volume":"38","author":"Lu","year":"2018","journal-title":"Med. Res. Rev."},{"issue":"8","key":"2026073102203262000_cit20","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/j.bmcl.2016.02.067","article-title":"Recent\nprogress on third generation\ncovalent EGFR inhibitors","volume":"26","author":"Cheng","year":"2016","journal-title":"Bioorg. Med. Chem.\nLett."},{"issue":"2","key":"2026073102203262000_cit21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib\nin Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"2026073102203262000_cit22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40265-022-01695-2","article-title":"Aumolertinib: A\nReview in Non-Small Cell Lung Cancer","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"issue":"10","key":"2026073102203262000_cit23","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.jtho.2022.08.016","article-title":"And Still\nThey Come Over Troubled Waters: Can Asia\u2019s\nThird-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib,\nRezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect\nGlobal Treatment of EGFR+ NSCLC","volume":"17","author":"Lau","year":"2022","journal-title":"J. Thorac.\nOncol."},{"issue":"15","key":"2026073102203262000_cit24","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s40265-021-01588-w","article-title":"Furmonertinib:\nFirst Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"2026073102203262000_cit25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.665253","article-title":"SH-1028, An Irreversible\nThird-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in\nNon-Small Cell Lung Cancer","volume":"12","author":"Han","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"15","key":"2026073102203262000_cit26","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s40265-023-01946-w","article-title":"Befotertinib:\nFirst Approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"2026073102203262000_cit27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12943-020-01202-9","article-title":"Discovery of a Novel\nThird-Generation EGFR Inhibitor and Identification\nof a Potential Combination Strategy to Overcome Resistance","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol. Cancer"},{"issue":"1","key":"2026073102203262000_cit28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced\nNSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"2026073102203262000_cit29","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed\nin EGFR T790M\u2013Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N.\nEngl. J. Med."},{"issue":"6","key":"2026073102203262000_cit30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1177\/1753465816670498","article-title":"Osimertinib in the Treatment of Patients with Epidermal\nGrowth Factor Receptor T790M Mutation-Positive Metastatic Non-Small\nCell Lung Cancer: Clinical Trial Evidence and Experience","volume":"10","author":"Sullivan","year":"2016","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"2","key":"2026073102203262000_cit31","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1021\/acs.jmedchem.1c00876","article-title":"Emerging Approaches\nto Overcome Acquired\nDrug Resistance Obstacles to Osimertinib in Non\u2013Small-Cell\nLung Cancer","volume":"65","author":"Shaikh","year":"2022","journal-title":"J. Med. Chem."},{"issue":"7605","key":"2026073102203262000_cit32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming\nEGFR(T790M) and EGFR(C797S) Resistance with\nMutant-Selective Allosteric Inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"issue":"7","key":"2026073102203262000_cit33","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/2159-8290.CD-18-0903","article-title":"Single and Dual Targeting of Mutant EGFR with\nan Allosteric Inhibitor","volume":"9","author":"To","year":"2019","journal-title":"Cancer Discovery"},{"issue":"4","key":"2026073102203262000_cit34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s43018-022-00351-8","article-title":"An Allosteric Inhibitor Against the Therapy-Resistant\nMutant Forms of EGFR in Non-Small Cell Lung Cancer","volume":"3","author":"To","year":"2022","journal-title":"Nat. Cancer"},{"issue":"10","key":"2026073102203262000_cit35","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1039\/D4MD00384E","article-title":"Next-generation EGFR tyrosine kinase\ninhibitors to\novercome C797S mutation in non-small cell lung cancer (2019\u20132024)","volume":"15","author":"Das","year":"2024","journal-title":"RSC Med. Chem."},{"issue":"22","key":"2026073102203262000_cit36","doi-asserted-by":"publisher","first-page":"10272","DOI":"10.1021\/acs.jmedchem.9b01169","article-title":"Start\nSelective and Rigidify: The Discovery Path Toward\na Next Generation of EGFR Tyrosine Kinase Inhibitors","volume":"62","author":"Engelhardt","year":"2019","journal-title":"J. Med. Chem."},{"issue":"9","key":"2026073102203262000_cit37","doi-asserted-by":"publisher","first-page":"6840","DOI":"10.1021\/acs.jmedchem.2c00168","article-title":"Conformational Constrained\n4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine\nDerivatives as New Fourth-Generation Epidermal Growth Factor Receptor\nInhibitors Targeting T790M\/C797S Mutations","volume":"65","author":"Chen","year":"2022","journal-title":"J. Med. Chem."},{"issue":"22","key":"2026073102203262000_cit38","doi-asserted-by":"publisher","first-page":"20531","DOI":"10.1021\/acs.jmedchem.4c01975","article-title":"Design, Synthesis, and\nBiological Evaluation of Novel\nDiaminopyrimidine Macrocycles as Fourth Generation Reversible EGFR\nInhibitors That Overcome Clinical Resistance to Osimertinib Mediated\nby C797S Mutation","volume":"67","author":"Hu","year":"2024","journal-title":"J. Med. Chem."},{"key":"2026073102203262000_cit39","doi-asserted-by":"publisher","first-page":"14768","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib Combined\nwith Anti-EGFR Antibody Overcomes Osimertinib Resistance in EGFR-Mutated\nNon-Small-Cell Lung Cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat. Commun."},{"issue":"18","key":"2026073102203262000_cit40","doi-asserted-by":"publisher","first-page":"13704","DOI":"10.1021\/acs.jmedchem.1c01055","article-title":"Potent and Selective\nInhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated\nResistance","volume":"64","author":"Finlay","year":"2021","journal-title":"J. Med. Chem."},{"issue":"13_Suppl","key":"2026073102203262000_cit41","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1158\/1538-7445.AM2019-1320","article-title":"Abstract\n1320: Preclinical Evaluation of TQB3804, a\nPotent EGFR C797S Inhibitor","volume":"79","author":"Liu","year":"2019","journal-title":"Cancer Res."},{"issue":"11","key":"2026073102203262000_cit42","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-20-0229","article-title":"CH7233163\nOvercomes\nOsimertinib-Resistant EGFR-Del19\/T790M\/C797S Mutation","volume":"19","author":"Kashima","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"15","key":"2026073102203262000_cit43","doi-asserted-by":"publisher","first-page":"10359","DOI":"10.1021\/acs.jmedchem.2c00704","article-title":"Discovery\nof BLU-945, a Reversible, Potent, and Wild-Type-Sparing\nNext-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell\nLung Cancer","volume":"65","author":"Eno","year":"2022","journal-title":"J. Med. Chem."},{"issue":"10","key":"2026073102203262000_cit44","doi-asserted-by":"publisher","first-page":"6849","DOI":"10.1021\/acs.jmedchem.3c00277","article-title":"Discovery\nof Potent and Wild-Type-Sparing Fourth-Generation\nEGFR Inhibitors for Treatment of Osimertinib-Resistance NSCLC","volume":"66","author":"Dong","year":"2023","journal-title":"J. Med. Chem."},{"issue":"21","key":"2026073102203262000_cit45","doi-asserted-by":"publisher","first-page":"14633","DOI":"10.1021\/acs.jmedchem.3c01165","article-title":"Discovery\nof Novel Fourth-Generation EGFR Inhibitors\nto Overcome C797S-Mediated Resistance","volume":"66","author":"Zhu","year":"2023","journal-title":"J. Med.\nChem."},{"issue":"1","key":"2026073102203262000_cit46","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114296","article-title":"A New ALK Inhibitor Overcomes Resistance to First- and Second-Generation\nInhibitors in NSCLC","volume":"14","author":"Lu","year":"2022","journal-title":"EMBO Mol. Med."},{"issue":"11","key":"2026073102203262000_cit47","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive\nAnalysis of Kinase Inhibitor Selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat.\nBiotechnol."},{"issue":"2","key":"2026073102203262000_cit48","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: Improving the Speed and Accuracy of\nDocking with a New Scoring Function, Efficient Optimization, and Multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"issue":"8","key":"2026073102203262000_cit49","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0:\nNew Docking Methods, Expanded Force Field, and Python Bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"issue":"Pt 8","key":"2026073102203262000_cit50","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1107\/S0907444906019949","article-title":"HKL-3000: The Integration\nof Data Reduction and Structure Solution\u2500from Diffraction Images\nto an Initial Model in Minutes","volume":"62","author":"Minor","year":"2006","journal-title":"Acta Crystallogr.\nD: Biol. Crystallogr."},{"issue":"Pt 4","key":"2026073102203262000_cit51","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser Crystallographic Software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"issue":"15","key":"2026073102203262000_cit52","doi-asserted-by":"publisher","first-page":"8502","DOI":"10.1021\/acs.jmedchem.0c00891","article-title":"Structural Basis of\nAZD9291 Selectivity for EGFR T790M","volume":"63","author":"Yan","year":"2020","journal-title":"J. Med.\nChem."},{"issue":"Pt 12 Pt 1","key":"2026073102203262000_cit53","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: Model-Building Tools for Molecular\nGraphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. D: Biol. Crystallogr."},{"issue":"Pt 2","key":"2026073102203262000_cit54","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: A Comprehensive Python-Based System\nfor Macromolecular Structure Solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta\nCrystallogr. D: Biol. Crystallogr."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c01320","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/18\/19205\/66296948\/acs.jmedchem.5c01320.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/18\/19205\/66296948\/acs.jmedchem.5c01320.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:20:41Z","timestamp":1785478841000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/18\/19205\/5234902\/Discovery-of-Potent-and-Selective-Pyrrolo-2-3-d"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":54,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9,9]]},"published-print":{"date-parts":[[2025,9,25]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01320","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]}}}